Literature DB >> 16611001

Delivery strategies for siRNA-mediated gene silencing.

Ian R Gilmore1, Stephen P Fox, Andrew J Hollins, Saghir Akhtar.   

Abstract

RNA interference (RNAi) represents a promising new gene silencing technology for functional genomics and a potential therapeutic strategy for a variety of genetic diseases. RNAi involves the targeted post-transcriptional degradation of messenger RNA thereby inhibiting the synthesis of the desired protein. This effectively leads to silencing of gene expression. The effectors of this process are short interfering RNA (siRNA) duplexes (approximately 21-23nt) that are key intermediaries in the specific degradation of target mRNA following incorporation into the RNA-induced silencing complex (RISC) in the cytosol. However, due to the large molecular weight and negative charge of siRNA duplexes the effective cellular uptake and intracellular delivery appear to represent a major challenge for the widespread use of RNAi in vivo. This review summarises some of the main delivery strategies that have been attempted for the transfection of siRNA to cells in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611001     DOI: 10.2174/156720106776359159

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  20 in total

1.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

2.  Efficient and gentle siRNA delivery by magnetofection.

Authors:  R Ensenauer; D Hartl; J Vockley; A A Roscher; U Fuchs
Journal:  Biotech Histochem       Date:  2010-03-18       Impact factor: 1.718

Review 3.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

4.  siRNA as a tool for investigating organogenesis: The pitfalls and the promises.

Authors:  Wen-Chin Lee; Rachel Berry; Peter Hohenstein; Jamie Davies
Journal:  Organogenesis       Date:  2008-07       Impact factor: 2.500

5.  Rapid and efficient technique for the production of condensed DNA and RNA nanoparticles using thermal cycling.

Authors:  V N Danilevich
Journal:  Dokl Biochem Biophys       Date:  2012-05-05       Impact factor: 0.788

Review 6.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application.

Authors:  Aimee L Jackson; Peter S Linsley
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

7.  Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles.

Authors:  Won Ho Kong; Ki Hyun Bae; Sung Duk Jo; Jee Seon Kim; Tae Gwan Park
Journal:  Pharm Res       Date:  2011-08-13       Impact factor: 4.200

Review 8.  New short interfering RNA-based therapies for glomerulonephritis.

Authors:  Hideki Shimizu; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

9.  Melittin derived peptides for nanoparticle based siRNA transfection.

Authors:  Kirk K Hou; Hua Pan; Gregory M Lanza; Samuel A Wickline
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

10.  Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier.

Authors:  Hyunmin Kang; Md Rowshon Alam; Vidula Dixit; Michael Fisher; Rudy L Juliano
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.